Cargando…

Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study

PURPOSE: To validate the clinical efficacy of the recently developed EUTOS long-term survival (ELTS) score in a real-world setting. PATIENTS AND METHODS: A total of 479 chronic myeloid leukemia (CML) patients treated with frontline imatinib between January 2010 and December 2017 were enrolled in thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xiawan, Bai, Yanliang, Shi, Mingyue, Zhang, Wanjun, Niu, Junwei, Wu, Chengye, Zhang, Lei, Xu, Zhiwei, Liu, Xiang, Chen, Yuqing, Sun, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039071/ https://www.ncbi.nlm.nih.gov/pubmed/32110103 http://dx.doi.org/10.2147/CMAR.S237467

Ejemplares similares

The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells
por: Shi, Mingyue, et al.
Publicado: (2019)

Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapy
por: Xia, Leiming, et al.
Publicado: (2015)

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
por: Pfirrmann, Markus, et al.
Publicado: (2020)

Prognostic and predictive implications of Sokal, Euro and EUTOS scores in chronic myeloid leukaemia in the imatinib era—experience from a tertiary oncology centre in Southern India
por: Kuntegowdanahalli, Lakshmaiah Chinnagiriyappa, et al.
Publicado: (2016)

Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
por: Millot, Frédéric, et al.
Publicado: (2017)

Lin28A/CENPE Promoting the Proliferation and Chemoresistance of Acute Myeloid Leukemia
por: Shi, Mingyue, et al.
Publicado: (2021)

Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
por: Zhang, Xiao-Shuai, et al.
Publicado: (2021)

The EUTOS long‐term survival score predicts disease‐specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice‐based cohort
por: Sato, Eriko, et al.
Publicado: (2020)

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
por: Schäfer, Vivien, et al.
Publicado: (2021)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

The Prognostic Significance of C-Reactive Protein to Albumin Ratio in Newly Diagnosed Acute Myeloid Leukaemia Patients
por: Dou, Liurui, et al.
Publicado: (2022)

Acute promyelocytic leukemia with myelofibrosis: A case report and literature review
por: Xiao, Mengyu, et al.
Publicado: (2021)

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
por: Adattini, Josephine A., et al.
Publicado: (2022)

Evaluating and monitoring bone marrow hypoplasia in adults with aplastic anemia via high-resolution iliac magnetic resonance imaging in the current era
por: Yang, Xiawan, et al.
Publicado: (2019)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia
por: Zhang, Tianzhuo, et al.
Publicado: (2020)

Outcome of Frontline Treatment with “Generic” Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study
por: Entasoltan, B., et al.
Publicado: (2017)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
por: Scerni, Ana Carolina Costa, et al.
Publicado: (2009)

Gynecomastia in a Boy with Chronic Myeloid Leukemia during Imatinib Therapy
por: Tavil, Betül, et al.
Publicado: (2013)

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
por: Angriman, Federico, et al.
Publicado: (2015)

Imatinib-induced dental hyperpigmentation in chronic myeloid leukemia in an adult female
por: Agrawal, Prabhat, et al.
Publicado: (2015)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Imatinib-induced Extensive Hyperpigmentation in a Case of Chronic Myeloid Leukemia
por: Balasubramanian, Pradeep, et al.
Publicado: (2015)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sd1tf4b5ldgppk5mklcvk4gv97